摘要
目的探讨罗格列酮治疗2型糖尿病的临床疗效。方法将口服磺脲类降糖药血糖控制不满意的2型糖尿病患者88例随机分为治疗组和对照组各44例,对照组在磺脲类降糖药物的基础上加服盐酸二甲双胍250mg,3次/d,治疗组加服罗格列酮4mg,1次/d,疗程均为12周,比较治疗前后两组的空腹血糖(FBG)、餐后2h血糖(2hPG)、糖化血红蛋白(HbAlc)、空腹胰岛素(FINS)、总胆固醇(Tc)、甘油三脂(TG)、高密度脂蛋白胆固醇(HDL-c)、低密度脂蛋白胆固醇(LDI-c)的变化。结果两组治疗后与治疗前比较FBG、2hBG、HbA1C、FINS、Tc、TG、HDL-c、LDL-c均显著降低,差异有统计学意义(P<0.05),而治疗组与对照组比较经治疗后上述指标均明显降低,HDL-C增高,差异有统计学意义(P<0.05)。结论罗格列酮治疗2型糖尿病不但能改善胰岛素抵抗、降低血糖、改善脂质代谢紊乱,还能延缓糖尿病的发展及降低发生血管并发症的危险,从而改善患者的远期预后,且治疗后无明显不良反应,值得临床推广使用。
Objective To investigate the rosiglitazone in treatment of type 2 diabetes clinical efficacy.Methods Oral sulfonylurea hypoglycemic blood glucose control not satisfied patients with type 2 diabetes 88 patients randomly divided into treatment group and control group each 44 cases,the control group on the basis of sulfonylurea plus metformin 250mg,3 times / day,treatment group took rosiglitazone 4mg,1 times / day,with a course of 12 weeks,obsere the two groups before and after treatment fasting blood glucose（FBG）,postprandial 2h plasma glucose（2hPG）,glycosylated hemoglobin（HbAlc）,fasting insulin（FINS）,total cholesterol（Tc）,triglycerides（TG）,high density lipoprotein cholesterol（HDL-c）,low-density lipoprotein cholesterol（LDI-c） changes.Results After treatment,compared with before treatment FBG,2hBG,HbA1C,FINS,Tc,TG,HDL-c,LDL-c were significantly lower,the difference was statistically significant（P0.05）,while the treatment group and the control group after treatment significantly reduced the above indexes,HDL-C increased significantly（P0.05）.Conclusions Rosiglitazone treatment of type 2 diabetes can not only improve insulin resistance,lower blood sugar,improve lipid metabolism,but also delay the development of diabetes and reduce the risk of vascular complications,thus improving long-term prognosis of patients,and no adverse reaction after treatment,worthy of clinical use.
出处
《医药论坛杂志》
2011年第3期57-58,61,共3页
Journal of Medical Forum
